Total Payments
$121,377
2024 Payments
$1,711
Companies
9
Transactions
160
Medicare Patients
92
Medicare Billing
$11,901
Payment Breakdown by Category
Consulting$65,802 (54.2%)
Travel$43,117 (35.5%)
Food & Beverage$5,248 (4.3%)
Research$3,852 (3.2%)
Other$3,355 (2.8%)
Education$4.54 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $65,802 | 18 | 54.2% |
| Travel and Lodging | $43,117 | 37 | 35.5% |
| Food and Beverage | $5,248 | 94 | 4.3% |
| Unspecified | $3,852 | 3 | 3.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,355 | 7 | 2.8% |
| Education | $4.54 | 1 | 0.0% |
Payments by Type
General
$117,526
157 transactions
Research
$3,852
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $43,745 | 98 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $32,955 | 20 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $24,840 | 18 | $0 (2019) |
| Genentech, Inc. | $9,227 | 8 | $0 (2020) |
| F. Hoffmann-La Roche AG | $6,852 | 4 | $0 (2024) |
| Genentech USA, Inc. | $2,704 | 7 | $0 (2018) |
| Celgene Corporation | $875.12 | 3 | $0 (2017) |
| La Jolla Pharmaceutical Company | $133.09 | 1 | $0 (2023) |
| United Therapeutics Corporation | $46.79 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,711 | 6 | F. Hoffmann-La Roche AG ($1,505) |
| 2023 | $13,770 | 14 | Boehringer Ingelheim International GmbH ($13,618) |
| 2022 | $794.47 | 5 | Boehringer Ingelheim Pharmaceuticals, Inc. ($794.47) |
| 2021 | $3,308 | 4 | F. Hoffmann-La Roche AG ($2,346) |
| 2020 | $9,708 | 13 | Genentech, Inc. ($3,360) |
| 2019 | $43,903 | 42 | E.R. Squibb & Sons, L.L.C. ($24,840) |
| 2018 | $28,090 | 28 | Boehringer Ingelheim International GmbH ($15,143) |
| 2017 | $20,094 | 48 | Boehringer Ingelheim Pharmaceuticals, Inc. ($16,565) |
All Payment Transactions
160 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $28.62 | General |
| Category: RESPIRATORY | ||||||
| 07/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: RESPIRATORY | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Actemra (Biological) | — | In-kind items and services | $1,505.17 | Research |
| Study: Long Term Follow Up Study of Patients with COVID 19 Associated Pneumonia Who Participated in a Desig • Category: Immunology | ||||||
| 05/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $78.62 | General |
| 05/21/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $46.79 | General |
| 04/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $34.72 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Travel and Lodging | In-kind items and services | $11,296.88 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Travel and Lodging | In-kind items and services | $540.47 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $100.63 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $67.84 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $7.09 | General |
| Category: RESPIRATORY | ||||||
| 11/07/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Travel and Lodging | In-kind items and services | $920.89 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Travel and Lodging | In-kind items and services | $342.22 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $68.00 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $68.00 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2023 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $66.00 | General |
| Category: RESPIRATORY | ||||||
| 05/20/2023 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $133.09 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 12/20/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $338.12 | General |
| Category: RESPIRATORY | ||||||
| 10/01/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $117.23 | General |
| Category: RESPIRATORY | ||||||
| 05/17/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $89.98 | General |
| 05/15/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $124.57 | General |
| 05/15/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $124.57 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOCILIZUMAB AND REMDESIVIR IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA | F. Hoffmann-La Roche AG | $1,929 | 1 |
| Long Term Follow Up Study of Patients with COVID 19 Associated Pneumonia Who Participated in a Desig | F. Hoffmann-La Roche AG | $1,505 | 1 |
| TOCILIZUMAB AND REMDESIVIR IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA A RANDOMIZED CLINICAL TRIAL | F. Hoffmann-La Roche AG | $417.86 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 21 | 61 | $11,163 | $3,048 |
| 2022 | 1 | 36 | 64 | $14,288 | $3,648 |
| 2021 | 1 | 20 | 44 | $10,780 | $3,338 |
| 2020 | 1 | 15 | 28 | $5,992 | $1,868 |
Total Patients
92
Total Services
197
Medicare Billing
$11,901
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 21 | 61 | $11,163 | $3,048 | 27.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 36 | $9,108 | $2,131 | 23.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 15 | 28 | $5,180 | $1,517 | 29.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 20 | 44 | $10,780 | $3,338 | 31.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 28 | $5,992 | $1,868 | 31.2% |
About Dr. Ivan Rosas, M.D
Dr. Ivan Rosas, M.D is a Critical Care Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427023852.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ivan Rosas, M.D has received a total of $121,377 in payments from pharmaceutical and medical device companies, with $1,711 received in 2024. These payments were reported across 160 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($65,802).
As a Medicare-enrolled provider, Rosas has provided services to 92 Medicare beneficiaries, totaling 197 services with total Medicare billing of $11,901. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Pulmonary Disease
- Location Houston, TX
- Active Since 02/21/2006
- Last Updated 10/31/2024
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1427023852
Products in Payments
- OFEV (Drug) $53,410
- ORENCIA (Biological) $24,840
- Actemra (Biological) $7,212
- Esbriet (Biological) $5,867
- Non-Covered Product (Drug) $2,501
- GILOTRIF (Drug) $525.73
- GIAPREZA (Drug) $133.09
- Xolair (Biological) $112.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Houston
Edwin Parsley, D.o, D.O
Critical Care Medicine — Payments: $251,404
Critical Care Medicine $251,404
Faisal Masud, M.d, M.D
Critical Care Medicine — Payments: $195,867
Critical Care Medicine $195,867
Dr. Bindu Akkanti, M.d, M.D
Critical Care Medicine — Payments: $133,512
Critical Care Medicine $133,512
Sergio Trevino Castillo, M.d, M.D
Critical Care Medicine — Payments: $132,750
Critical Care Medicine $132,750
Dr. Dileep Puppala, M.d, M.D
Critical Care Medicine — Payments: $105,456
Critical Care Medicine $105,456
Dr. Kyle Stephens, Md, MD
Critical Care Medicine — Payments: $24,711
Critical Care Medicine $24,711